Clinical Trials Logo

Filter by:
NCT ID: NCT05867160 Recruiting - Epilepsy Clinical Trials

Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study

Start date: May 2, 2023
Phase:
Study type: Observational

The purpose of this study is to describe the effectiveness of the adjunctive ASM treatment on the clinical response, safety profile and quality of life of patients affected by focal onset seizures in a real-world setting.

NCT ID: NCT05867121 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: October 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.

NCT ID: NCT05865886 Recruiting - Cystic Fibrosis Clinical Trials

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairaflyâ„¢)

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis. The purpose of this study is to find out whether a medicine called BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis. Participants are put randomly into 2 groups. One group takes BI 1291583 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1291583 tablets but do not contain any medicine. Participants in both groups take 1 tablet once a day for 12 weeks. Participants have twice the chance of being placed in the BI 1291583 group than in the placebo group. Participants are in the study for about 6 months. During this time, they visit the study site 7 times. At the visits, the doctors check the health of the participants and note any health problems that could have been caused by BI 1291583.

NCT ID: NCT05865093 Recruiting - Visual Impairment Clinical Trials

Early Visual Functions in Patients at Risk of Developing Cerebral Visual Impairment. A Pilot Study

Start date: July 1, 2022
Phase:
Study type: Observational

The aim of the study is to assess visual function from neonatal age to 36 months of age in infants at risk of visual impairment due to brain lesion or ocular pathology

NCT ID: NCT05864833 Recruiting - Orthopedic Disorder Clinical Trials

METabolism After Orthopedic Surgery

Start date: September 6, 2023
Phase:
Study type: Observational

This prospective observational study evaluates changes in resting basal metabolic rate in 51 adult patients undergoing elective major orthopedic surgery (hip, knee, or spine surgery).

NCT ID: NCT05864820 Recruiting - Anthropometry Clinical Trials

Photogrammetric Scan System for Body Composition Analysis

Start date: April 18, 2023
Phase:
Study type: Observational

This observational study evaluates the goodness of the IGOODI photogrammetric scan system in measuring anthropometry and estimating the body composition of 75 healthy subjects, comparing the results with the measurements taken using methods used in clinical practice, including body circumferences and bioimpedance analysis.

NCT ID: NCT05864768 Recruiting - Clinical trials for Periodontal Diseases

The Role of Diet in Periodontal Inflammation: A Controlled Clinical Study

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Diet can influence the body's healing and repair mechanisms. A dietary imbalance obviously cannot trigger periodontal disease in the absence of a primum movens, which is bacterial plaque. However, it can condition its severity and extent by altering the permeability of the oral mucosa, the effectiveness of the immune response and the reparative potential of the gingival tissues. Nutraceuticals is the science that studies the effects of the so-called food-drug, i.e. those foods that contain substances capable of performing a pharmacological function, modifying the functions of the organism. In particular, some molecules that are assimilated through various foods are able to penetrate the cell nucleus and influence, through an epigenetic mechanism, the expression or otherwise of some genes. The aim of our controlled study is to understand whether a vegetarian/vegan diet can be considered as protective for periodontal health compared to an omnivorous diet. For this purpose, we used a test group of 22 omnivorous subjects and a control group of 22 vegetarian/vegan patients in which experimental gingivitis was induced.

NCT ID: NCT05862740 Recruiting - Ovarian Cancer Clinical Trials

ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer

ULTRA-LAP
Start date: January 2, 2022
Phase: N/A
Study type: Interventional

ULTRA-LAP is a prospective study is to investigate the safety, efficacy and feasibility of laparoscopic debulking surgery (LDS) for the treatment of patients with advanced ovarian cancer. The outcomes to measure are: - Safety: the rate of patients experiencing intra- and post-operative early and late morbidities (within the hospitalization and up to 60 days from surgery) - Efficacy: the rate of patients in which the surgical target set pre-operatively (complete resection) is achieved by laparoscopy. - Feasibility: the rate of patients who have their procedure completed by laparoscopy Patients will undergo laparoscopic debulking surgery (LDS) if the surgical target can be met. If it cannot be achieved by laparoscopy the surgeon will convert to laparotomy.

NCT ID: NCT05861336 Recruiting - Pancreatic Cancer Clinical Trials

GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

OVERPASS
Start date: June 14, 2023
Phase: Phase 2
Study type: Interventional

Single-arm, prospective, phase II study to evaluate safety and activity of an induction therapy with Gemcitabine (GEM) and nab-paclitaxel plus Losartan followed by Stereotactic Radiotherapy (SBRT) in patients affected by Locally Advanced Pancreatic Cancer (LAPC).

NCT ID: NCT05860673 Recruiting - Clinical trials for Adolescent Idiopathic Scoliosis

Minimally Invasive Surgery vs Standard Posterior Approach in the Treatment of Developmental Idiopathic Scoliosis

Start date: July 15, 2023
Phase: N/A
Study type: Interventional

This is a randomized trial with 1:1 allocation. The aim of the study is to evaluate clinical and radiographic outcomes in patients with developmental age idiopathic scoliosis treated with mini invasive scoliosis surgery (MIS) technique versus posterior spinal fusion (PSF) technique through clinical and radiographic evaluations.